AgingResearch.NewsJoin free

Summit Therapeutics

CompanyUnited States

Summit Therapeutics develops one asset, in phase 3 (ivonescimab in breast cancer). Mostly antibody acting on inflammation, VEGFA and PDCD1; based in the United States.

1
Asset
Furthest stage
Phase 3
2
Trials
0
Signals

Pipeline

1

  • ivonescimab

    Bispecific antibody blocks PD-1 and VEGF to enhance antitumor immunity and inhibit angiogenesis.

    Phase 3, Antibody, Inflammation, VEGFA, breast cancer, lung cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials11
  • Similar companies6

Papers

Intelligence